Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults

Inclusion Criteria: * Male or female subjects between 18 and 65 years of age (inclusive). * BMI≥28 but \< 40.0 kg/m2 at screening or randomization，or BMI≥24.0 kg/m2 but \< 28 kg/m2 with any of the following: 1. Hypertension 2. Impaired fasting glucose or impaired glucose tolerance 3. Dyslipidemia 4. Obstructive sleep apnea syndrome * At least one previous failure to lose weight through lifestyle modification was defined as \< 5% weight loss after ≥3 months of lifestyle modification. Exclusion Criteria: * Weight change ≥5% as reported or documented. Previous diagnosis of type 1, type 2, or any other type of diabetes. * Diagnosis of overweight or obesity due to other diseases or medications. * History or family history of medullary thyroid carcinoma, C cell hyperplasia, or multiple endocrine neoplasia type 2. * Have diseases or conditions that affect gastric emptying or gastrointestinal absorption of nutrients, such as bariatric surgery or other gastrectomy, irritable bowel syndrome, dyspepsia, chronic pancreatitis, etc. Or a history of acute pancreatitis or acute gallbladder disease within 3 months before signing ICF. * GLP-1R agonist use within 6 months prior to signing ICF. * Use of hypoglycemic drugs within 3 months before signing ICF.